OPK-8801001

OPK-8801001 is a preclinical-stage long-acting growth hormone receptor antagonist being developed by OPKO Biologics for the treatment of acromegaly. The drug utilizes OPKO's proprietary C-terminal peptide (CTP) technology, which involves attaching a specific peptide sequence to the recombinant protein to extend its serum half-life. By blocking the growth hormone receptor, OPK-8801001 reduces growth hormone (GH) signaling, which is pathologically elevated in patients with acromegaly. The goal of this long-acting formulation is to allow for once-weekly subcutaneous administration, potentially improving patient compliance and quality of life compared to existing daily or more frequent therapies.

Other names

Long Acting hGH AntagonistLong-acting growth hormone receptor antagonist